MedTrace Logo

Response of Hepatic Tumors to Radioembolization

NCT01775280 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-06-09

No results posted yet for this study

Summary

The study enrolls patients with non-resectable or borderline resectable hepatocellular carcinoma (HCC), intraheaptic choalngiocarcinoma (IHCC) or colorectal cancer metastasis. Patients are not a candidates for liver transplantation and have only limited extrahepatic disease. All patients are treated with radioembolization. Primary endpoint is the percentage of patients that can be downstaged to resectability.

Secondary endpoints are radiologic response to radioembolization,tissue response to radiomembolization and systemic immune response and intra-tumoral T-cell response to radioembolization.

* Trial with radiotherapy

Conditions

Interventions

RADIATION

Injection of Ytttrium-90 microspheres into the hepatic artery

INjection of Y-90 particles into the hepatic artery using endovascular access

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Erik Schadde, MD · University Hospital Zurich, Division of Visceral and Transplant Surgery

  • Niklaus Schaefer, MD · University Hospital Zurich, Division of Nuclear Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01775280 on ClinicalTrials.gov